Free gift on orders $400+ · pick BPC-157, NAD+ 500MG, MOTS-C 10MG & more•Complimentary 2-day shipping over $250• Same-day dispatch before 12 PM MT• New batches made in the USA• ≥99% average purity · independent U.S. lab testing• Free gift on orders $400+ · pick BPC-157, NAD+ 500MG, MOTS-C 10MG & more•Complimentary 2-day shipping over $250• Same-day dispatch before 12 PM MT• New batches made in the USA• ≥99% average purity · independent U.S. lab testing•
0
Trust built by transparency. Scan the vial, read the lab’s own report.

Research overview

Tesamorelin

Updated Nov 1, 20264 min readResearch use only
Research overview4 min readUpdated Nov 1, 2026

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) that keeps all 44 amino acids of the native hormone and adds one small chemical group: a trans-3-hexenoyl cap on the N-terminal tyrosine.

For laboratory work, its interest lies in that design choice. Most synthetic GHRH analogs use the shortened 1-29 fragment, while tesamorelin keeps the full-length chain and protects it at a single site.

TESAMORELIN is currently out of stock at Rogue Compounds while the next batch is tested. View TESAMORELIN →

At a glance

  • Class: Synthetic GHRH(1-44) analog peptide; GHRH receptor agonist
  • Origin: Theratechnologies (code TH9507); non-clinical profile published by Ferdinandi and colleagues in 2007
  • Structure: 44 residues of human GHRH with an N-terminal trans-3-hexenoyl group and C-terminal amide; C221H366N72O67S; 5136.0 g/mol; CAS 218949-48-5
  • Main research areas: GHRH receptor pharmacology, N-terminal stabilization, GH/IGF-1 axis and adipose tissue biology, analytical detection
  • Regulatory status: Research chemical, not for human use

Structure and origin

Human GHRH is a 44-residue amidated peptide whose hypothalamic structure was established by Ling and colleagues in 1984 (Ling et al., 1984). Native GHRH is broken down within minutes in plasma. The main route is cleavage of the Tyr1-Ala2 dipeptide by dipeptidyl peptidase-4, which leaves an inactive GHRH(3-44).

Two broad strategies emerged to address this. One shortens the peptide to residues 1-29 and replaces vulnerable amino acids, the route taken by sermorelin derivatives and CJC-1295. The other, used for tesamorelin, leaves the sequence untouched and blocks the N-terminus chemically. A trans-3-hexenoic acid is attached to the amino group of Tyr1, forming an amide. The six-carbon unsaturated acyl group hinders aminopeptidase access while leaving the receptor-binding residues in place.

Keeping residues 30-44 makes tesamorelin the closest stabilized analog of full-length GHRH available. Whether that C-terminal region contributes meaningfully to receptor binding, stability or tissue distribution, compared with 1-29 analogs, is one of the questions the molecule allows researchers to ask.

Mechanism: what the research shows

Tesamorelin acts at the GHRH receptor, a class B G protein-coupled receptor cloned from pituitary tissue in 1992 (Mayo, 1992). Activation couples to Gs, adenylate cyclase and cAMP, which drives GH synthesis and release from anterior pituitary somatotrophs and supports somatotroph proliferation (Mayo et al., 2000). The GH that is released then acts on the liver and other tissues to raise IGF-1.

The studies compared its GH-releasing activity with native human GHRH, examined its stability, and covered safety pharmacology and toxicology (Ferdinandi et al., 2007). Because the analog works upstream of GH, its effects remain subject to normal feedback, including somatostatin inhibition and IGF-1 negative feedback, a point often noted when contrasting GHRH analogs with direct administration of GH in experimental settings.

Key areas of study

GHRH receptor signaling

As a full-length agonist, tesamorelin is a useful comparator in receptor assays alongside sermorelin and other 1-29 analogs. The receptor expression systems that make these comparisons possible trace back to the cloning work (Mayo, 1992).

GH/IGF-1 axis and adipose tissue

Most published work on tesamorelin concerns its effect on the GH axis and on fat distribution, particularly visceral adipose tissue. These studies are cited here for regulatory and historical context.

Analytical detection

Because GHRH analogs are prohibited in sport, the hexenoyl-modified peptide and its metabolites are targets for mass spectrometry methods in anti-doping laboratories. The N-terminal cap gives the molecule a distinctive mass signature compared with native GHRH.

What the evidence does not show

  • Published preclinical data come largely from the developer’s own program; independent preclinical studies are relatively few.
  • Direct comparisons between full-length tesamorelin and stabilized 1-29 analogs under identical conditions are scarce, so the practical value of residues 30-44 is still an open question.
  • Rodent and dog GH responses do not map one-to-one onto other species, and the GH axis is strongly influenced by age, sex and nutritional state in all of them.

Regulatory status

Rogue Compounds sells this material as a research chemical, not for human use. It is sold for laboratory research only.

Handling and storage in the lab

The lyophilized peptide should be kept sealed and refrigerated at 2–8°C (36–46°F), protected from light.

Sourcing and documentation

Tesamorelin is produced in small batches for Rogue Compounds. Every vial carries a batch number and a QR code that opens the independent U.S. testing lab’s own report for that batch. The same batch COA is posted on the product page and in the COA Library.

Comparing GHRH analogs? See Sermorelin vs CJC-1295 vs Tesamorelin for a side-by-side look at how they differ in structure, stability and duration in research models.

View Tesamorelin on Rogue Compounds

References

  1. Ling N, et al. Proc Natl Acad Sci USA. 1984;81:4302-4306. PMID 6431406
  2. Mayo KE. Mol Endocrinol. 1992;6(10):1734-1744. PMID 1333056
  3. Mayo KE, et al. Recent Prog Horm Res. 2000;55:237-266. PMID 11036940
  4. Ferdinandi ES, et al. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. PMID 17214611
  5. Falutz J, et al. J Acquir Immune Defic Syndr. 2010;53(3):311-322. PMID 20101189
  6. Dhillon S. Drugs. 2011;71(8):1071-1091. PMID 21668043

Research use only. Rogue Compounds products are sold strictly for laboratory research. They are not for human or veterinary use, and nothing in this article is medical advice. The studies cited here describe published research, not this product or any use of it.

Trust built by transparency. Scan the vial, read the lab’s own report.

Research peptides & laboratory compounds. Built by researchers. For researchers.

Support

Disclaimer

The statements provided herein have not been assessed by the Food and Drug Administration. These products are not designed to diagnose, treat, cure, or prevent any disease. Rogue Compounds does not operate as a compounding pharmacy or chemical compounding facility as defined under 503A/503B of the Federal Food, Drug, and Cosmetic Act. The products available on this website are intended for research use only and are not suitable for human or animal consumption.

© 2026 Rogue Compounds. All rights reserved.

For research use only